In the old situation within specialised hospitals, we assumed that multiple single-gene tests were performed, minimally three for NSCLC patients (a multigene panel, HER2/EGFR, and ALK, ROS, RET, or MET) and two for melanoma patients (BRAF and NRAS or KIT). This evidence concerns the gene KIT and non-small cell lung carcinoma.